Home/Filings/4/0000899243-21-034460
4//SEC Filing

Claremount VII Associates, L.P. 4

Accession 0000899243-21-034460

CIK 0001568651other

Filed

Aug 26, 8:00 PM ET

Accepted

Aug 27, 8:32 PM ET

Size

17.2 KB

Accession

0000899243-21-034460

Insider Transaction Report

Form 4
Period: 2021-08-25
Transactions
  • Purchase

    Class A Common Stock

    2021-08-26$13.74/sh+204,811$2,814,8201,505,389 total(indirect: See footnote)
  • Purchase

    Class A Common Stock

    2021-08-25$13.18/sh+31,794$418,9081,300,578 total(indirect: See footnote)
  • Purchase

    Class A Common Stock

    2021-08-27$14.05/sh+217,590$3,057,9881,722,979 total(indirect: See footnote)
Transactions
  • Purchase

    Class A Common Stock

    2021-08-27$14.05/sh+217,590$3,057,9881,722,979 total(indirect: See footnote)
  • Purchase

    Class A Common Stock

    2021-08-25$13.18/sh+31,794$418,9081,300,578 total(indirect: See footnote)
  • Purchase

    Class A Common Stock

    2021-08-26$13.74/sh+204,811$2,814,8201,505,389 total(indirect: See footnote)
Transactions
  • Purchase

    Class A Common Stock

    2021-08-26$13.74/sh+204,811$2,814,8201,505,389 total(indirect: See footnote)
  • Purchase

    Class A Common Stock

    2021-08-27$14.05/sh+217,590$3,057,9881,722,979 total(indirect: See footnote)
  • Purchase

    Class A Common Stock

    2021-08-25$13.18/sh+31,794$418,9081,300,578 total(indirect: See footnote)
Transactions
  • Purchase

    Class A Common Stock

    2021-08-25$13.18/sh+31,794$418,9081,300,578 total(indirect: See footnote)
  • Purchase

    Class A Common Stock

    2021-08-27$14.05/sh+217,590$3,057,9881,722,979 total(indirect: See footnote)
  • Purchase

    Class A Common Stock

    2021-08-26$13.74/sh+204,811$2,814,8201,505,389 total(indirect: See footnote)
Footnotes (4)
  • [F1]Represents (i) 31,415 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 379 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.09 to $13.20, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,285,094 shares are held directly by Thrive VII Growth and 15,484 shares are held directly by Claremount VII.
  • [F2]Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein.
  • [F3]Represents (i) 202,373 shares purchased by Thrive VII Growth and (ii) 2,438 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.39 to $14.06, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,487,467 shares are held directly by Thrive VII Growth and 17,922 shares are held directly by Claremount VII.
  • [F4]Represents (i) 215,000 shares purchased by Thrive VII Growth and (ii) 2,590 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.72 to $14.26, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 1,702,467 shares are held directly by Thrive VII Growth and 20,512 shares are held directly by Claremount VII.

Issuer

Oscar Health, Inc.

CIK 0001568651

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001841808

Filing Metadata

Form type
4
Filed
Aug 26, 8:00 PM ET
Accepted
Aug 27, 8:32 PM ET
Size
17.2 KB